a
study
out of the university of alabama at birmingham (uab) showed that use of the diabetes drug metformin prior to a covid-19 diagnosis had a significant effect on a person’s chances of dying.
in fact, the racially diverse study saw a threefold decrease in mortality for people with type 2 diabetes even after correcting for sex, age, race, obesity and other health factors, anath shalev, m.d., director of uab’s comprehensive diabetes center and leader of the study, told
uab news
.
“since similar results have now been obtained in different populations from around the world — including china, france and a unitedhealthcare analysis — this suggests that the observed reduction in mortality risk associated with metformin use in subjects with type 2 diabetes and covid-19 might be generalizable,” she said.
the study, published in the journal frontiers in endocrinology, included 25,326 patients tested for covid-19 at uab between feb. 26 and june 22 of last year.
researchers focused the study on how both insulin and metformin — the two most common medications for diabetes – affected patient outcomes related to covid-19 and saw dramatic results for those who were taking metformin, while insulin had no effect on mortality.